Matt Gline: Yes. So, I’ll start with the first one of that which is, I don’t think our view of the POS and DM would change at all depending on the outcome in SLE. The biology of brepo is very clear. We have six positive large well run Phase 2 studies and SLEs is known to be ethical place, so. I think overall there will be no change in our view of likelihood of success in DM as a function of any kind of outcome in SLE, honestly in either direction. If Brepo works great necessarily I’m not sure it will materially affect our view of probability in DM. At this point brepo has presented itself as an agent and it’s just a question of finding the right therapeutic applications for its profile. So that’s on that question. On the general strategy, and I can see this clearly enough.
If we never do another BD deal, and that is not we are definitely going to do more VD deals. But if we never do other BD deal we are sitting on — We think today the most exciting late-stage I&I portfolio between FcRn and brepo and became on others and there is no question in my mind that frankly, I mean we knew this from our competitors FcRn alone can support that kind of value-creation right alone the drug-like brepocitinib which certainly again pursuing a different strategy but Rinvoq is on-track to do fantastically well and. I think we have an agent that has some real competitive advantages versus Rinvoq with particularly activities. So, you know I think there is no question to me that we don’t need to do BD for the next major leg of growth for us.
That’s it. Practically speaking, if you’re asking me what I expect, I expect to see significant value creation, outside of our late-stage pipeline as well. New opportunities just because we’ve always been active because the opportunity set is literally as rich now as it has ever been in terms of the quality of things that we see and we expect to take full advantage of that given our current capital position.
Unidentified Analyst: Thank you very much. Appreciate it.
Matt Gline: My pleasure.
Operator: Thank you. And this will end the Q&A portion of the conference. I would now like to turn the conference back to Matt Gline for closing remarks.
Matt Gline: Yes, thank you. I just want to say thank you again to everybody to the Roivant teams to all of our investors to the patients and investigators, our studies to our partners. It’s been a phenomenal year. This is probably not the last time we get on the phone together given the amount of data coming. But just want to thank everybody for following along and what has felt like I really exciting moment for us. So, if we don’t talk before Thanksgiving, and I guess again it’s possible that we will, but if we don’t talk before Thanksgiving have a great holiday for those who celebrate it, and I’m looking forward to getting on the phone again soon. Thank you very much.
Operator: This concludes today’s conference call. Thank you all for participating you may now disconnect and have a pleasant day.
